Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025

Investment Strategy - The average annual return of the S&P 500 is approximately 10%, suggesting that doubling capital typically takes around 7 years [1] - Achieving 100% returns by 2025 requires taking risks, with a recommendation to limit exposure to risky stocks to about 10% of capital [1] Arrowhead Pharmaceuticals (ARWR) - Arrowhead Pharmaceuticals is a well-established pharmaceutical company with a strong pipeline, currently priced at $24 [2] - The company has multiple drugs in phase 3 testing and is positioned to become a leader in the cardiometabolic niche [2] - Arrowhead has two treatments for non-alcoholic steatohepatitis (NASH), one licensed to GSK, with potential for insurance coverage due to weight loss efficacy [3] YETI (YETI) - YETI is known for outdoor products and has seen a 13% increase in sales in the first quarter, with international sales spiking by 32% [5] - Earnings rose by 50% to 18 cents, and the company initiated a $100 million share repurchase program [6] - YETI stock is currently priced under $40, with analysts predicting a rise to $85, and some forecasts suggesting a potential high of $600 [6] NovoCure Limited (NVCR) - NovoCure Limited focuses on oncology and reported revenues of $138.5 million, up 13%, with 3,845 patients receiving therapies [7] - The company is conducting multiple Phase 3 trials, indicating potential for increased revenue streams [7] - It is working on commercializing tumor treating fields, which could provide further investment upside [8] Joby Aviation (JOBY) - Joby Aviation is recognized as a leading player in the flying car sector, with recent earnings showing an EPS beat [10] - The company has published final airworthiness criteria for its electric air taxi service and plans to deliver two aircraft to MacDill Air Base in 2025 [10] - Joby has exclusive rights to operate air taxis in Dubai and is expanding its presence in the UAE, showing resilience compared to competitors [11] Viking Therapeutics (VKTX) - Viking Therapeutics has seen a 300% increase in value in 2024, with shares trading at $80 [12] - The company's VK2809 therapeutic is in Phase 2b trials for NASH, with potential for weight loss benefits [12] - Therapeutics with secondary indications are more likely to receive insurance coverage, enhancing revenue potential [13] Matthews International (MATW) - Matthews International is primarily involved in the memorialization segment, accounting for 85% of revenues, and is currently priced at $28 [15] - The company has paid down over $27 million in debt recently and is also involved in warehouse automation, providing growth opportunities [16] Navitas Semiconductor (NVTS) - Navitas Semiconductor, a small firm trading under $5, reported a 73% revenue increase in the first quarter [17] - The company specializes in gallium nitride power integrated circuits, which are gaining traction in mobile fast charging and AI data centers [17] - Navitas anticipates continued rapid adoption of its products, positioning it as a promising investment in the semiconductor sector [18]